Get the Stockscreener App
3.12
12.23%
0.34
Pre-market:
3.21
0.09
+2.88%
Evotec Se Adr stock is traded at $3.12, with a volume of 110.41K.
It is up +12.23% in the last 24 hours and up +35.06% over the past month.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
See More
Previous Close:
$2.78
Open:
$3.06
24h Volume:
110.41K
Relative Volume:
0.81
Market Cap:
$1.11B
Revenue:
$890.87M
Net Income/Loss:
$-115.85M
P/E Ratio:
-9.5676
EPS:
-0.3261
Net Cash Flow:
$-104.29M
1W Performance:
+20.93%
1M Performance:
+35.06%
6M Performance:
-19.59%
1Y Performance:
-5.45%
1-Day Range:
$3.04
$3.14
1-Week Range:
$2.59
$3.14
52-Week Range:
$2.308
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.12 | 934.14M | 890.87M | -115.85M | -104.29M | -0.3261 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Berenberg | Buy |
| Apr-24-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Oct-07-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jul-29-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-11-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock new upside? - AD HOC NEWS
BofA reiterates Evotec stock Underperform rating on execution concerns - Investing.com
Evotec (NASDAQ: EVO) pivots to asset-light model and boosts 2025 liquidity - Stock Titan
Evotec Q4 2025 slides: strong finish masks segment headwinds By Investing.com - Investing.com South Africa
Evotec Q4 2025 slides: strong finish masks segment headwinds - Investing.com
Earnings call transcript: Evotec SE ADR Q4 2025 sees revenue growth, stock surges - Investing.com
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal By Investing.com - Investing.com South Africa
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Benzinga
Evotec's B2B Partner Search Initiative: Unlocking Strategic Collaborations in Drug Discovery for Nor - AD HOC NEWS
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026 - ChartMill
Evotec appoints Ashiq Khan as chief commercial officer - Investing.com
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer - ChartMill
Evotec SE Stock: Drug Discovery Leader Faces Restructuring Challenges Ahead of Key Earnings - AD HOC NEWS
Evotec SE stock faces pressure amid biotech sector volatility and partnership updates - AD HOC NEWS
Evotec SE Stock Faces Pressure Amid Biotech Sector Headwinds and Pipeline Updates in Q1 2026 - AD HOC NEWS
JustEvotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - ChartMill
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Evotec Aktie | DE0005664809 | ETR:EVT | News & Aktienkurs | FRA:EVT - LYNX Online Broker
Evotec shares surge 8% as Berenberg initiates with “buy” on partner value By Investing.com - Investing.com South Africa
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? - Finviz
Financial Review: Evotec (NASDAQ:EVO) & Savara (NASDAQ:SVRA) - Defense World
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Chartmill
Taxes of Evotec SE Sponsored ADR – LSX:A0QZ3J - TradingView — Track All Markets
EvotecHow Low A Company May Go While Still Being Attractive (NASDAQ:EVO) - Seeking Alpha
Evotec AG Earnings Call: Resilience Amidst Challenges - MSN
Evotec AG Reports Strategic Shift Amid Mixed Performance - MSN
Annual General Meeting - Evotec
Investor Relations - Evotec
Evotec shares tumble 9% as drug discovery segment weakens - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Should I buy Evotec (EVO) - zacks.com
ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com Australia
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com UK
EVT Stock Price and Chart — XETR:EVT - TradingView
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com UK
The integrin repertoire drives YAP-dependent epithelial:stromal interactions during injury of the kidney glomerulus - Nature
Evotec SE Sponsored ADR Trade Ideas — LSX:A0QZ3J - TradingView — Track All Markets
Evotec Stock: Some Recovery Has Come, Much More Is Expected (NASDAQ:EVO) - Seeking Alpha
Evotec SE (NASDAQ: EVO) Announces Departure of Chief Operating Officer Dr. Craig Johnstone - Kalkine Media
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):